Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?

Date

06 Mar 2023

Session

Cocktail & Poster Display session

Presenters

Beatriz Alonso de Castro

Citation

Annals of Oncology (2023) 8 (1suppl_2): 100903-100903. 10.1016/esmoop/esmoop100903

Authors

B. Alonso de Castro1, M.I. Gomez Randulfe2, K. Ouali3, K. Beshiri4, J. Gavira Diaz5, C. Baldini6, S. Champiat4, J. Michot7, R. Bahleda8, F. Danlos9, A. Gazzah10, A. Hollebecque10, A. Bayle11, Y. Loriot12, A. Varga13, A. Marabelle14, S. Postel-Vinay14, S. Ponce Aix4

Author affiliations

  • 1 Drug Development Department (ditep), Institute Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 2 Oncology, CHUAC - Complexo Hospitalario Universitario A Coruña, 15006 - A Coruña/ES
  • 3 Medical Oncology Dept, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 4 Drug Development Department (ditep), Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 5 Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 6 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 7 Drug Developpement Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 8 Drug Development Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 9 Drug Development Department - Lrti, Gustave Roussy - INSERM U1015, 94805 - Villejuif/FR
  • 10 Ditep, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 11 Digestive Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 12 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 13 Ditep - Département D’innovation Thérapeutique Et D’essais Précoces, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 14 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif/FR

Resources

This content is available to ESMO members and event participants.

Abstract 41P

Background

Immunotherapy has revolutionized cancer treatment improving survival rates for many cancer types. Unfortunately, resistances are common and predictive biomarkers are needed. Microsatellite Instability-high (MSI-H) usually predicts response to ICB in all tumour types, whereas we need more studies focusing on tumour mutational burden (TMB) to predict its role as a pan-cancer biomarker. Recent investigations in murine models and cohorts of patients (pts) have shown that BRCA2 PV improved response and overall survival to ICB compared to BRCA1 PV. The aim of this study was to evaluate the response to ICB in BRCA PV and its relation with TMB, MSI-H and prior treatments.

Methods

We conducted an unicohort retrospective study, between May 2020 and November 2022, in metastatic pts carrying BRCA1 or BRCA2 somatic PV and treated with ICB in phase I/II trials at Institute Gustave Roussy (France). Genomic analysis were performed by NGS (liquid biopsy and tumor samples). Data was extracted from electronic medical record and analysed with SPSS software.

Results

A total of 44 pts were enrolled. Median age was 54.6 years [range 29–74 years], 46.7% were female. Lung cancer was the most common tumour (20.5%) in an heterogenic histologic cohort of pts. Median previous lines of treatment was 2.7 [range 0-4]. Tissue analysis revealed 21.1% MSI-H, 36.8% TMB high, 23.8% BRCA1 PV, 38.1% BRCA2 PV. Blood analysis showed 7.3% MSI-H, 52.4% TMB high, 40,5% BRCA1 PV, 52.4% BRCA2 PV. All pts received immunotherapy, 69.8% ICB. The Objective Response Rate (ORR) was 34.1%. Pts with BRCA2 PV presented a better ORR to ICB compared to those with BRCA1 PV (28% vs. 4%, p = 0,030). Mean TMB was lower in BRCA2 PV than in BRCA1 PV pts and median previous lines of treatment was higher in BRCA2 PV than in BRCA1 PV (2.5 vs. 2.0). We didn´t find a significant association between BRCA1/2 PV and MSI status. Duration of response (DoR) to ICB by more than 6 months tended to be higher in pts with BRCA2 PV than those with BRCA1 PV (32% vs. 16%, p = 0,512).

Conclusions

Pts with somatic BRCA2 PV had better ORR to ICB regardless of TMB, MSI and prior lines of treatment than those with BRCA1 PV. Further research should be carried out to confirm BRCA2 as a predictive pan-cancer biomarker to ICB in a larger cohort with BRCA WT pts as comparison.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

K. Beshiri: Financial Interests, Personal, Invited Speaker: Gustave Roussy. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.